Mehmet Ferit GÜRSU, Burkay YAKAR, Erhan ÖNALAN, Nevzat GOZEL, Elif MELEK

Association of Betatrophin, TNF-α and IL-6 with diabetic microvascular and macrovascular complications

Aim: The most important goal in the treatment of Diabetes Mellitus is to protect patients from micro and macro complications.Inflammatory cytokines and betatrophin have been reported to play a role in diabetic micro and macro complications. This studyaimed to investigate the effect of serum Betatrophin, TNF-α and IL-6 levels on diabetic micro and macro complications in patientswith type 2 Diabetes Mellitus.Materials and Methods: This case-control study was conducted with 91 type 2 Diabetes Mellitus (T2DM) patients betweenJanuary-December 2018. Case series with 91 patients divided into three groups were included; 31 T2DM patients without diabeticcomplications (group 1=control), 30 patients with diabetic microvascular complications (group 2) and 30 patients with diabeticmacrovasculer complications (group 3). Blood was collected to evaluate biochemical parameters, TNF-α, IL-6 and betatrophin.Results: Betatrophin level was high in patients with renitopathy (p=0.042) and diabetic foot (p=0.036). TNF-α levels were higherin patients with both microvascular and macrovascular complications compared to the control group (p

PDF

___

1. Goldmann L, Schafer AI (editors). Goldman-Cecil Medicine. Textbook of Internal Medicine 2015;1150- 2075
2. International Diabetes Federation. Annual Report 2015. https://www.idf.org/component/attachments. html?id=743&task=download access date 01.12.2019 3.
3. Alberti KG, Zimmet P. Global burden of disease-- where does diabetes mellitus fit in? Nat Rev Endocrinol 2013;9:258-60.
4. International Diabetes Federation. IDF Diabetes Atlas, 7th ed. 2015. https://www.idf.org/e-library/ epidemiology-research/diabetes-atlas/13-diabetesatlas-seventh-edition.html access date 01.12.2019.
5. Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1 beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv) 2011;53:44-50.
6. Desislava N, Georgieva K, Sivkova NP, et al. Serum inflammatory cytokines IL-1β, IL-6, TNF-α and VEGF have influence on the development of diabetic retinopathy. Folia Medica 2011;53:44-50.
7. Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2002;16:163-70.
8. Chen CC, Susanto H, Chuang WH, et al. Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function. Cardiovasc Diabetol 2016;15:3.
9. Fang C, Huang Y, Guo H, et al. Lipasin, a biomarker of diabetic retinopathy. Diabetes Res Clin Pract 2016;115:96-8.
10. Wang YY, Zhang D, Jiang ZY, et al. Positive Association Between Betatrophin and Diabetic Retinopathy Risk in Type 2 Diabetes Patients. Horm Metab Res 2016;48:169-73.
11. Dong CX, Song CP, Zhang CP, et al. Clinical and experimental study on angiopoietin-like protein 8 associated with proliferative diabetic retinopathy. Int J Ophthalmol 2017;10:1819-23.
12. Lu Q, Lu L, Chen W, et al. Expression of angiopoietinlike protein 8 correlates with VEGF in patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2017;255:1515-23.
13. Li S, Liu D, Li L, et al. Circulating Betatrophin in Patients with Type 2 Diabetes: A Meta-Analysis. J Diabetes Res 2016;2016:6194750.
14. Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol 2014;2014:6.
15. Ebert T, Kralisch S, Hoffmann A, et al. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocrinol Metab 2014;99:257-10.
16. Liuxue Y, Jianfei S, Xiaoxi Z, et al. Association of Serum Angiopoietin-Like Protein 8 With Albuminuria in Type 2 Diabetic Patients: Results From the GDMD Study in China. Front. Endocrinol 2018;9:414.
17. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8.
18. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004;21:203-7.
19. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42- 7.
20. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835-9.
21. Villegas R, Liu S, Gao YT, et al. Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. Arch Intern Med 2007;167:2310-6.
22. Hernández-Da Mota SE, Soto-Bahena JJ, ViverosSandoval ME, et al. Pro-inflammatory serum cytokines in diabetic retinopathy. Cir Cir 2015;83:100-6.
23. George L. King. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79(8 Suppl):1527-34.
24. Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorld Journal 2006;6:908-17.
25. Phosat C, Panprathip P, Chumpathat N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocr Disord 2017;17:44.
26. Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetes Care 2013;36:166-75.
27. Rehman K, Akash MSH, Liaqat A, et al. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. Crit Rev Eukaryot Gene Expr 2017;27:229-36.
28. Senthilkumar GP, Anithalekshmi MS, Yasir M, et al. Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. Diabetes Metab Syndr 2018;12:23-6.
29. Al-Rubeaan K, Siddiqui K, Al-Ghonaim MA, et al. Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep 2017;7:2684.